The goal of the Data Bank and BioRepository (DBBR) Resource is to meet the scientific needs of CCSG Program members by providing biospecimens procured under rigorous conditions in collection, processing and storage, linked with clinical and epidemiological data, for translational studies of cancer etiology, detection, treatment and prognosis. DBBR Clinical Research Associates enroll patients at 20 clinics running over 200 services, with the majority consented and blood samples drawn prior to surgery, ensuring minimal effects of cancer treatment on circulating biomarkers. Blood samples are collected alongside existing clinical laboratory orders by the phlebotomy service at RPCI, and transported to the laboratory through the pneumatic tube system, where they are processed into numerous 0.5ml straws of plasma, serum, red blood cells and buffy coat with an automated process, and stored in liquid nitrogen within 1 hour of blood draw. The DBBR actively maintains an inventory of over 700,000 prospectively banked samples from more than 17,000 participants. Family members and friends accompanying patients, visitors to RPCI, and community members identified through outreach and education events are also enrolled into DBBR as non-cancer controls. Detailed annotation and tracking procedures are in place, and the entire DBBR operation is managed through the RPCI Laboratory Information Management System (LIMS) and linked with PRN and CDN to enable supply of liquid specimens along with tumor specimens and high-quality clinical data. Samples and data are available through a chargeback mechanism to CCSG Program members and include those from patients diagnosed with breast, lung, GYN, GU, Gl, head and neck, melanoma, soft tissue sarcoma, lymphoma, and neurological cancers as well as bone marrow transplant patients. This Resource is unique for translational research because it provides high-quality epidemiological data linked to rigorously processed biospecimens that are characterized by pathological and clinical information, thereby actively facilitating studies of cancer risk, progression and outcome in an environment that ensures confidentiality. First priority for use is given to peer-review-funded CCSG members;second priority to non-peer-review-funded CCSG members;third priority to non-members and academic collaborators;and last priority to external users. During the reporting period, the Data Bank and BioRepository Shared Resource has served 6 research programs and 27 total users. Of the users, 84% overall utilization was by 18 CCSG members with peer-reviewed funding;8% overall utilization was by 5 CCSG members without peer-reviewed funding;and 8% utilization was by other users. The CCSG support provides 8% of the overall proposed budget.
The DBBR Shared Resource provides rigorously collected biospecimens matched with clinical and epidemiological data from cancer patients and non-cancer controls. These samples and data are readily available to scientists to conduct research on numerous questions related to cancer causes and outcomes. This obviates the need to prospectively conduct new studies, and allows for immediate translation of findings from the laboratory to populations.
|Miller, James A; Harris, Kassem; Roche, Charles et al. (2018) Sarcopenia is a predictor of outcomes after lobectomy. J Thorac Dis 10:432-440|
|Fenstermaker, Robert A; Figel, Sheila A; Qiu, Jingxin et al. (2018) Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res 24:2642-2652|
|Bhat, Tariq A; Kalathil, Suresh Gopi; Bogner, Paul N et al. (2018) Secondhand Smoke Induces Inflammation and Impairs Immunity to Respiratory Infections. J Immunol 200:2927-2940|
|Merzianu, Mihai; Groman, Adrienne; Hutson, Alan et al. (2018) Trends in Bone Marrow Sampling and Core Biopsy Specimen Adequacy in the United States and Canada: A Multicenter Study. Am J Clin Pathol 150:393-405|
|Qin, Bo; Llanos, Adana A M; Lin, Yong et al. (2018) Validity of self-reported weight, height, and body mass index among African American breast cancer survivors. J Cancer Surviv 12:460-468|
|Qiao, Guanxi; Chen, Minhui; Bucsek, Mark J et al. (2018) Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response. Front Immunol 9:164|
|Muramatsu, Masashi; Akakura, Shin; Gao, Lingqiu et al. (2018) SSeCKS/Akap12 suppresses metastatic melanoma lung colonization by attenuating Src-mediated pre-metastatic niche crosstalk. Oncotarget 9:33515-33527|
|Kumar, Sandeep; Inigo, Joseph R; Kumar, Rahul et al. (2018) Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett 413:82-93|
|Liu, Chunhong; Yu, Tao; Xing, Zhuo et al. (2018) Triplications of human chromosome 21 orthologous regions in mice result in expansion of megakaryocyte-erythroid progenitors and reduction of granulocyte-macrophage progenitors. Oncotarget 9:4773-4786|
|Cimato, Thomas R; Conway, Alexis; Nichols, Julianne et al. (2018) CD133 expression in circulating hematopoietic progenitor cells. Cytometry B Clin Cytom :|
Showing the most recent 10 out of 1555 publications